Satsuma Pharmaceuticals, Inc.
STSA
$0.00
Change (1 day)
$8.08
Year High
$0.59
Year Low
Categories
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals, Inc. (STSA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2022 | -16,291,000 | 8.12 M | 54.94 M | 54.81 M | |
| 2021 | -14,755,000 | 8.49 M | 109.83 M | 99.85 M | |
| 2020 | -33,294,000 | 9.1 M | 81.03 M | 73.79 M | |
| 2019 | -17,825,000 | 10.94 M | 126.28 M | 114.74 M | |
| 2018 | -240,000 | 18.51 M | 6.38 M | 5.4 M |